Pfizer Seeks FDA Authorization for COVID-19 Booster Shots in 16- and 17-Year-Olds

Pfizer Seeks FDA Authorization for COVID-19 Booster Shots in 16- and 17-Year-Olds
A health care worker prepares a dose of the Pfizer-BioNTech COVID-19 vaccine at a UHN COVID-19 vaccine clinic in Toronto on Jan. 7, 2021. Nathan Denette/The Canadian Press
Isabel van Brugen
Updated:

Pfizer CEO and Chairman Albert Bourla on Tuesday announced that the company and its partner BioNTech have submitted a request to the U.S. Food and Drug Administration (FDA) seeking to expand authorization for its COVID-19 booster shot for use in 16- and 17-year-olds.

It comes after U.S. regulators last week expanded the eligibility for a booster dose of Pfizer and BioNTech’s COVID-19 vaccine to all adults 18 and over, to be administered at least six months after receiving the second shot.

Isabel van Brugen
Isabel van Brugen
Reporter
Isabel van Brugen is an award-winning journalist. She holds a master's in newspaper journalism from City, University of London.
twitter
Related Topics